Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Shares Outstanding (Weighted Average) (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Shares Outstanding (Weighted Average) readings, the most recent being $6.7 million for Q4 2024.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 72.7% to $6.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $6.7 million, a 72.7% decrease, with the full-year FY2024 number at $6.7 million, down 72.7% from a year prior.
  • Shares Outstanding (Weighted Average) hit $6.7 million in Q4 2024 for Unicycive Therapeutics, up from $5.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $34.9 million in Q1 2024 to a low of $3.8 million in Q2 2024.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $15.1 million (2022), compared with a mean of $16.2 million.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 129.2% in 2024, down 83.43% in 2024.
  • Unicycive Therapeutics' Shares Outstanding (Weighted Average) stood at $11.7 million in 2021, then grew by 28.96% to $15.1 million in 2022, then soared by 62.98% to $24.5 million in 2023, then plummeted by 72.7% to $6.7 million in 2024.
  • The last three reported values for Shares Outstanding (Weighted Average) were $6.7 million (Q4 2024), $5.4 million (Q3 2024), and $3.8 million (Q2 2024) per Business Quant data.